Incorporation of biologic factors for the staging of de novo stage IV breast cancer

Zhen-Yu He\textsuperscript{1,4}, Chen-Lu Lian\textsuperscript{2,4}, Jun Wang\textsuperscript{2,4}, Jian Lei\textsuperscript{3}, Li Hua\textsuperscript{3}, Juan Zhou\textsuperscript{3,5,6} and San-Gang Wu\textsuperscript{2,6}

This study aimed to investigate the prognostic value of biologic factors, including histological grade, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status in de novo stage IV breast cancer. Based on eligibility, patient data deposited between 2010 and 2014 were collected from the surveillance, epidemiology, and end results database. The receiver operating characteristics curve, Kaplan–Meier analysis, and Cox proportional hazard analysis were used for analysis. We included 8725 patients with a median 3-year breast cancer-specific survival (BCSS) of 52.6%. Higher histologic grade, HER2-negative, ER-negative, and PR-negative disease were significantly associated with lower BCSS in the multivariate prognostic analysis. A risk score staging system separated patients into four risk groups. The risk score was assigned according to a point system: 1 point for grade 3, 1 point if hormone receptor-negative, and 1 point if HER2-negative. The 3-year BCSS was 76.3%, 64.5%, 48.5%, and 23.7% in patients with 0, 1, 2, and 3 points, respectively, with a median BCSS of 72, 52, 35, and 16 months, respectively ($P < 0.001$). The multivariate prognostic analysis showed that the risk score staging system was an independent prognostic factor associated with BCSS. Patients with a higher risk score had a lower BCSS. Sensitivity analyses replicated similar findings after stratification according to tumor stage, nodal stage, the sites of distant metastasis, and the number of distant metastasis. In conclusion, our risk score staging system shows promise for the prognostic stratification of de novo stage IV breast cancer.

npj Breast Cancer (2020) 6:43; https://doi.org/10.1038/s41523-020-00186-5

INTRODUCTION

De novo stage IV breast cancer is a rare disease that is considered to be incurable and accounting for ~5% of newly diagnosed breast cancer cases\textsuperscript{1}. Earlier, the majority of patients with this type of cancer did not survive for more than 5 years after diagnosis, with a 5-year overall survival (OS) of ~20%\textsuperscript{2}. However, with advances in chemotherapy, target therapy, and endocrine therapy, the 5-year OS has now increased to 40% in the modern era of multidisciplinary management\textsuperscript{3,4}. The 5-year OS could reach 50% in hormone receptor (HoR)-positive (\textasciitilde) tumors, but the 3-year breast cancer-specific survival (BCSS) and OS for de novo stage IV triple-negative breast cancer are still lower than 20%\textsuperscript{5,6}. Further, the median OS for human epidermal growth factor receptor-2 positive (HER2\textasciitilde) tumors in this population has also been reported to reach 60 months after trastuzumab-based therapy\textsuperscript{7,8}, and the prognosis of de novo stage IV disease was found to be better than those with recurrent tumors\textsuperscript{9–16}.

Gene expression studies have suggested that the histological grade is more closely related to the molecular composition of breast cancer than the primary tumor size and lymph node status\textsuperscript{11,12}. Tumor grade is an important biologic factor that has been incorporated into the most recent breast cancer staging system of the 8th American Joint Committee on Cancer (AJCC)\textsuperscript{13}. The 8th AJCC breast cancer staging system has significantly changed from the 7th AJCC anatomical staging system. Biologic factors in breast cancer, including histological grade, HER2, estrogen receptor (ER), and progesterone receptor (PR) status, have been now included in the traditional anatomic primary tumor (T), regional lymph nodes (N), and distant metastasis (M) staging system to create new stages\textsuperscript{13}. Several studies have verified that the new staging system is more accurate in predicting prognosis than the 7th AJCC staging system\textsuperscript{14–17}. However, the new staging system only includes patients with non-metastatic disease; those in de novo stage IV disease were excluded\textsuperscript{18}. In previous studies, including ours, have shown that the HoR\textasciitilde/HER2\textasciitilde+ subtype was associated with significantly better BCSS than the HoR\textasciitilde+/HER2\textasciitilde− and HoR\textasciitilde−/HER2\textasciitilde+ subtypes in de novo stage IV disease, while those with HoR\textasciitilde/HER2\textasciitilde− disease had the worst survival\textsuperscript{19–22}. Therefore, tumor biologic factors are significant predictors for both responses to therapy and prognosis in non-metastatic as well as metastatic disease.

The de novo stage IV subgroup is an important enrolled population in clinical trials. Further, there is a significant difference in the survival of this population. Therefore, it is critical to investigate whether the biologic factors based on the 8th AJCC stages could also apply to de novo stage IV disease. In light of this, we explored the prognostic value of biological factors for this disease using a population-based cohort from the surveillance, epidemiology, and end results (SEER) program.

RESULTS

Patient characteristics

We identified 8725 patients that met the criteria of this study. Figure 1 depicts the patient selection flowchart for this study. The demographic, clinicopathological, treatment, and distant metastasis data of the patients are listed in Table 1. Of the entire cohort, 83.0%, 76.0%, and 51.2% had infiltrating ductal carcinoma, node-positive disease, and T3-4 disease, respectively. In addition, 8.5%, 42.5%, and 49.0% of patients presented with...
well-differentiated (G1), moderately differentiated (G2), and poorly/undifferentiated (G3) tumors, respectively. Moreover, 5665 (64.9%), 1218 (14.0%), 718 (8.2%), and 1124 (12.9%) patients had the HoR+/HER2−, HoR+/HER2+, HoR−/HER2+, and HoR−/HER2− subtypes, respectively.

A total of 5561 (63.7%), 2551 (29.2%), 2089 (23.9%), and 536 (6.1%) patients presented with bone, lung, liver, and brain metastasis, respectively. In patients for whom information about these four metastatic sites were available (n = 7497), 4963 (66.2%), 1908 (25.5%), 546 (7.3%), and 80 (1.1%) had one, two, three, and four metastatic sites, respectively.

Survival and prognosis
Within a median follow-up of 29 months (range, 0–83 months), there were 5326 deaths observed, out of which 4653 were related to breast cancer. The 3-year BCSS was 52.6%, and the median BCSS was 39 months.

Multivariate analysis showed that higher histologic grade, HER2-negative, single HoR-positive (ER-positive or PR-positive), and double HoR-negative (ER-negative and PR-negative) status were significantly associated with lower BCSS (Table 2). Moreover, age, race/ethnicity, histology, surgery, chemotherapy, bone metastasis, lung metastasis, liver metastasis, and brain metastasis were also identified as independent prognostic factors correlated with BCSS. However, the BCSS was comparable among patients with stage T1 and T2 disease, and BCSS was also comparable among patients with stage N0, N1, N2, and N3 disease.

According to the status of the included biologic factors, such as tumor grade, HER2 status, ER status, and PR status, a total of 24 subgroups were reclassified (Table 3). Of these patients, no patients were assigned to the G1/HER2+/ER+/PR+ subgroup, and the top five common subgroups were G2/HER2−/ER+/PR+ (28.6%), G3/HER2+/ER+/PR+ (17.4%), G3/HER2−/ER−/PR− (10.7%), G1/HER2−/ER+/PR+ (7.1%), and G3/HER2+/ER−/PR− (6.1%). According to Kaplan–Meier analysis, significantly longer median BCSS was found in the G1/HER2+ subgroups and G1/HER2+/ER+/PR+ subgroups, and the median BCSS was not reached in these subgroups. The worst median BCSS was observed in three subgroups: G1/HER2−/ER−/PR+, G2/HER2−/ER−/PR+, and G3/HER2−/ER−/PR+, which had a median BCSS of 4, 10, and 11 months, respectively.

Table 1. Patients’ demographic, clinicopathological characteristics, treatment, and the patterns of distant metastasis (N = 8725).

| Variables | N (%) |
|-----------|-------|
| Age (years) Mean ± SD (range) | 59.7 ± 13.9 (19–103) |
| Race/ethnicity | |
| Non-Hispanic White | 5647 (64.7) |
| Non-Hispanic Black | 1467 (16.8) |
| Hispanic (All Races) | 941 (10.8) |
| Other | 658 (7.5) |
| Unknown | 12 (0.1) |
| Grade | |
| G1 | 743 (8.5) |
| G2 | 3704 (42.5) |
| G3 | 4278 (49.0) |
| Tumor stage | |
| T1 | 1294 (14.8) |
| T2 | 2968 (34.0) |
| T3 | 1550 (17.8) |
| T4 | 2913 (33.4) |
| Nodal stage | |
| N0 | 2098 (24.0) |
| N1 | 3914 (44.9) |
| N2 | 1183 (13.6) |
| N3 | 1530 (17.5) |
| Hormone receptor status | |
| ER+ and PR+ | 5400 (61.9) |
| ER+ or PR+ | 1483 (17.0) |
| ER− and PR− | 1842 (21.1) |
| HER2 status | |
| Negative | 6789 (77.8) |
| Positive | 1936 (22.2) |
| Surgery | |
| No | 4897 (56.1) |
| Yes | 3793 (43.5) |
| Unknown | 35 (0.4) |
| Radiotherapy | |
| No | 5327 (61.1) |
| Yes | 3166 (36.3) |
| Unknown | 232 (2.7) |
| Chemotherapy | |
| No | 3104 (35.6) |
| Yes | 5621 (64.4) |
| Bone metastasis | |
| No | 3164 (36.3) |
| Yes | 5561 (63.7) |
| Brain metastasis | |
| No | 8189 (93.9) |
| Yes | 536 (6.1) |
Risk score staging system

A previous study by Chavez–MacGregor et al. from University of Texas MD Anderson Cancer Center (MDACC) developed a risk score staging system based on a risk score of 0–3 assigned according to the histological grade (0 point for G1-2, 1 point for G3), ER status (0 point if ER-positive, 1 point if ER-negative), and HER2 status (0 point if HER2-positive, 1 point if HER2-negative) to stratify the prognosis of patients (Table 3)\(^*\). With the MDACC risk score staging system, the 3-year BCSS was 72.3%, 61.6%, 46.5%, and 23.7% in patients with 0, 1, 2, and 3 points, respectively, with a median BCSS of 69, 49, 33, and 15 months, respectively (Fig. 2a). In our study, the worst median BCSS was observed in the subgroups: G1-3/HER2−/ER−/PR−, which indicated that patients with single HoR-positive disease had inferior BCSS compared to those with double HoR-positive disease. Although there was a significant difference in BCSS between single HoR-positive and double HoR-negative diseases using the Kaplan–Meier analysis (\(P = 0.012\)), the survival curves were overlapped. Therefore, we integrated single HoR-positive and double HoR-negative cohorts into an aggressive subgroup. We developed another risk score staging system (SEER database) based on histological grade (0 point for G1-2, 1 point for G3), HER2 status (0 point if HER2-positive, 1 point if HER2-negative), HoR status (0 point if double HoR-positive, 1 point if single HoR-positive or double HoR-negative). The score ranges from 0 to 3, and BCSS could also be predicted according to this risk score. Within the SEER risk score staging system, the 3-year BCSS was 76.3%, 64.5%, 48.5%, and 23.7% in patients with 0, 1, 2, and 3 points, respectively, with a median BCSS of 72, 52, 35, and 16 months, respectively (Fig. 2b). The SEER risk score staging system was examined against the MDACC risk score staging system using the receiver operating characteristics (ROC) curve. The area under the curve (AUC) under the ROC curve of SEER risk score staging system (AUC = 0.628, 95% CI 0.618–0.638) was significantly higher than that of MDACC risk score staging system (AUC = 0.611, 95% CI 0.601–0.622) (\(P < 0.0001\)) (Fig. 3). The results indicated that the SEER risk score staging system had a better predictive performance for BCSS compared to the MDACC risk score staging system.

### Table 1 continued

| Variables | \(N (\%)\) |
|-----------|-------------|
| Liver metastasis | | |
| No | 6636 (76.1) |
| Yes | 2089 (23.9) |
| Lung metastasis | | |
| No | 6174 (70.8) |
| Yes | 2551 (29.2) |
| Other metastatic sites | | |
| No | 7497 (85.9) |
| Yes | 1228 (14.1) |
| Number of metastatic sites (\(n = 7497\)^* | | |
| 1 | 4963 (66.2) |
| 2 | 1908 (25.5) |
| 3 | 546 (7.3) |
| 4 | 80 (1.1) |

\(ER\) estrogen receptor, \(G1\) well-differentiated, \(G2\) moderately differentiated, \(G3\) poorly/undifferentiated, \(HER2\) human epidermal growth factor receptor-2, \(N\) nodal, \(PR\) progesterone receptor, \(SD\) standard deviation, \(T\) tumor.

\(^*\)Indicates four metastatic sites, including bone, brain, liver, and lung.

### Table 2. Multivariate prognostic analysis, including histologic grade, ER, PR, and HER2 status.

| Variables | HR | 95% CI | \(P\) |
|-----------|----|--------|------|
| Age (years) (continuous variable) | 1.015 | 1.013–1.018 | <0.001 |
| Race/ethnicity | | | |
| Non-Hispanic White | 1 | | |
| Non-Hispanic Black | 1.331 | 1.233–1.438 | <0.001 |
| Hispanic (All Races) | 1.023 | 0.928–1.128 | 0.646 |
| Other | 0.988 | 0.879–1.110 | 0.841 |
| Unknown | 0.262 | 0.065–1.049 | 0.058 |
| Grade | | | |
| G1 | 1 | | |
| G2 | 1.379 | 1.217–1.556 | <0.001 |
| G3 | 1.934 | 1.704–2.195 | <0.001 |
| Histological subtypes | | | |
| Infiltrating ductal carcinoma | 1 | | |
| Infiltrating lobular carcinoma | 1.213 | 1.096–1.342 | <0.001 |
| Other | 1.181 | 1.060–1.317 | 0.003 |
| Tumor stage | | | |
| T1 | 1 | | |
| T2 | 1.007 | 0.915–1.108 | 0.891 |
| T3 | 1.114 | 1.001–1.239 | 0.048 |
| T4 | 1.289 | 1.170–1.420 | <0.001 |
| Nodal stage | | | |
| N0 | 1 | | |
| N1 | 0.965 | 0.894–1.040 | 0.350 |
| N2 | 1.022 | 0.922–1.133 | 0.678 |
| N3 | 1.084 | 0.987–1.191 | 0.090 |
| Hormone receptor status | | | |
| ER+ and PR− | 1 | | |
| ER+ or PR+ | 1.772 | 1.639–1.916 | <0.001 |
| ER− and PR− | 2.261 | 2.078–2.459 | <0.001 |
| HER2 status | | | |
| Negative | 1 | | |
| Positive | 0.414 | 0.381–0.450 | <0.001 |
| Surgery | | | |
| No | 1 | | |
| Yes | 0.601 | 0.563–0.641 | <0.001 |
| Unknown | 1.146 | 0.737–1.781 | 0.546 |
| Radiotherapy | | | |
| No | 1 | | |
| Yes | 0.986 | 0.927–1.051 | 0.662 |
| Unknown | 0.807 | 0.656–0.992 | 0.042 |
| Chemotherapy | | | |
| No | 1 | | |
| Yes | 0.917 | 0.851–0.988 | 0.023 |
| Bone metastasis | | | |
| No | 1 | | |
| Yes | 1.266 | 1.187–1.350 | <0.001 |
| Brain metastasis | | | |
| No | 1 | | |
| Yes | 2.141 | 1.928–2.377 | <0.001 |
| Liver metastasis | | | |
| No | 1 | | |
| Yes | 1.771 | 1.655–1.895 | <0.001 |
| Lung metastasis | | | |
| No | 1 | | |
| Yes | 1.223 | 1.147–1.303 | <0.001 |
| Other metastatic sites | | | |
| No | 1 | | |
| Yes | 1.021 | 0.907–1.149 | 0.730 |

\(CI\) confidence interval, \(ER\) estrogen receptor, \(G1\) well-differentiated, \(G2\) moderately differentiated, \(G3\) poorly/undifferentiated, \(HER2\) human epidermal growth factor receptor-2, \(N\) nodal, \(HR\) hazard ratio, \(PR\) progesterone receptor, \(T\) tumor.

Published in partnership with the Breast Cancer Research Foundation
Prognostic value of the risk score staging system

We used multivariate prognostic analysis to assess the prognostic effect of the SEER risk score staging system based on BCSS (Table 4).

After adjustment for age, race/ethnicity, histology, T stage, N stage, surgery, chemotherapy, radiotherapy, and the sites of distant metastasis, the SEER risk score staging system was found to be an independent prognostic factor associated with BCSS. Patients with a higher risk score had a lower BCSS. When risk score 0 was used as a

Table 3. The median BCSS in 24 subgroups according to the histological grade, ER, PR, and HER2 status.

| Tumor grade | HER2 status | ER status | PR status | N (%) | Median BCSS (months) | Risk score (MDACC) | Risk score (SEER) |
|-------------|-------------|-----------|-----------|-------|----------------------|--------------------|-------------------|
| G1          | HER2+       | ER+       | PR+       | 18 (0.2) | NA                    | 0                  | 0                 |
| G1          | HER2+       | ER+       | PR−       | 5 (0.1)  | NA                    | 0                  | 1                 |
| G1          | HER2+       | ER−       | PR+       | NA      | NA                   | 1                  | 1                 |
| G1          | HER2+       | ER−       | PR−       | 4 (0.1)  | 72                    | 1                  | 1                 |
| G1          | HER2−       | ER+       | PR−       | 617 (7.1)| 63                    | 1                  | 1                 |
| G1          | HER2−       | ER+       | PR−       | 88 (1.0) | 35                    | 1                  | 2                 |
| G1          | HER2−       | ER−       | PR+       | 2 (0.1)  | 4                     | 2                  | 2                 |
| G1          | HER2−       | ER−       | PR−       | 9 (0.1)  | 18                    | 2                  | 2                 |
| G2          | HER2+       | ER+       | PR+       | 290 (3.3)| 72                    | 0                  | 0                 |
| G2          | HER2+       | ER+       | PR−       | 133 (1.5)| 47                    | 0                  | 1                 |
| G2          | HER2+       | ER−       | PR+       | 16 (0.2) | 39                    | 1                  | 1                 |
| G2          | HER2+       | ER−       | PR−       | 186 (2.1)| 49                    | 1                  | 1                 |
| G2          | HER2−       | ER+       | PR+       | 2493 (28.6)| 50              | 1                  | 1                 |
| G2          | HER2−       | ER+       | PR−       | 393 (4.5)| 27                    | 1                  | 2                 |
| G2          | HER2−       | ER−       | PR+       | 13 (0.1) | 10                    | 2                  | 2                 |
| G2          | HER2−       | ER−       | PR−       | 180 (2.1)| 17                    | 2                  | 2                 |
| G3          | HER2+       | ER+       | PR+       | 461 (5.3)| 65                    | 1                  | 1                 |
| G3          | HER2+       | ER+       | PR−       | 268 (3.1)| 44                    | 1                  | 2                 |
| G3          | HER2+       | ER−       | PR+       | 27 (0.3) | 52                    | 2                  | 2                 |
| G3          | HER2+       | ER−       | PR−       | 528 (6.1)| 49                    | 2                  | 2                 |
| G3          | HER2−       | ER+       | PR+       | 1521 (17.4)| 36              | 2                  | 2                 |
| G3          | HER2−       | ER+       | PR−       | 453 (5.2)| 20                    | 2                  | 3                 |
| G3          | HER2−       | ER−       | PR+       | 88 (1.0) | 11                    | 3                  | 3                 |
| G3          | HER2−       | ER−       | PR−       | 932 (10.7)| 15              | 3                  | 3                 |

BCSS breast cancer-specific survival, ER estrogen receptor, G1 well-differentiated, G2 moderately differentiated, G3 poorly/undifferentiated, HER2 human epidermal growth factor receptor-2, MDACC MD Anderson Cancer Center, NA none available, PR progesterone receptor, SEER surveillance, epidemiology, and end results.

Fig. 2 Comparison of breast cancer-specific survival by risk score. a MD Anderson Cancer Center risk score staging system; b SEER risk score staging system.

Prognostic value of the risk score staging system

We used multivariate prognostic analysis to assess the prognostic effect of the SEER risk score staging system based on BCSS (Table 4). After adjustment for age, race/ethnicity, histology, T stage, N stage, surgery, chemotherapy, radiotherapy, and the sites of distant metastasis, the SEER risk score staging system was found to be an independent prognostic factor associated with BCSS. Patients with a higher risk score had a lower BCSS. When risk score 0 was used as a
Fig. 3 Receiver operating characteristics analyses for prediction of breast cancer-specific survival with the two risk score staging systems. The SEER risk score staging system had a better predictive performance for breast cancer-specific survival compared to the MD Anderson Cancer Center risk score staging system.

reference, patients with risk score 1 was associated with significantly lower BCSS than those with risk score 0 (hazard ratio [HR] = 1.473, 95% confidence interval [CI] = 1.195–1.816, P < 0.001), patients with risk score 2 had a significantly lower BCSS than those with risk score 0 (HR = 2.437, 95% CI = 1.979–3.001, P < 0.001), patients with risk score 3 had a significantly lower BCSS compared to those with risk score 0 (HR = 5.092, 95% CI = 4.121–6.291, P < 0.001). Patients with risk score 3 was associated with significantly lower BCSS compared to those with risk score 1 (HR = 3.456, 95% CI = 3.182–3.754, P < 0.001) and risk score 2 (HR = 2.647, 95% CI = 2.459–2.848, P < 0.001). Sensitivity analyses replicated similar findings after stratification according to the T stage (Fig. 4a–d), N stage (Fig. 5a–d), the sites of distant metastasis (Fig. 6a–e), and the number of distant metastasis (Fig. 7a–c) (Table 5).

DISCUSSION

A primary limitation of the AJCC 8th stages is that it is limited to patients with non-metastatic breast cancer. It is critical to investigate whether the biologic factors based on the 8th AJCC stages could also be applied to breast cancer with de novo stage IV disease. In the present study, we used a population-based cohort from the SEER program to investigate the prognostic effect of biologic factors in de novo stage IV breast cancer. The current study indicated that the risk score staging system developed by the histological grade, HER2 status, ER status, and PR status might provide a better risk stratification for this population.

The findings in our study may have potential clinical implications in the current era of personalized therapy for de novo stage IV breast cancer. First, it provides a concise summary of the de novo stage IV breast cancer, which allows for efficient communication among clinicians and researchers. In addition, it also provides a framework for relaying prognostic stratification based on the sum of the tumor and biologic factors. According to this prognostic framework, the risk score staging system can be applied to determine the optimal treatment approach for individual patients. Moreover, it can more thoroughly and accurately assess the impact

### Table 4. Multivariate prognostic analysis, including risk score staging system.

| Variables                      | HR   | 95% CI       | P      |
|-------------------------------|------|--------------|--------|
| Age (years) (continuous variable) | 1.015 | 1.013–1.018 | <0.001 |
| Race/ethnicity                |      |              |        |
| Non-Hispanic White            | 1    |              |        |
| Non-Hispanic Black            | 1.334 | 1.235–1.441  | <0.001 |
| Hispanic (All Races)          | 1.010 | 0.916–1.114  | 0.844  |
| Other                         | 0.982 | 0.874–1.103  | 0.757  |
| Unknown                       | 0.264 | 0.066–1.059  | 0.606  |
| Histological subtypes         |      |              |        |
| Infiltrating ductal carcinoma | 1    |              |        |
| Infiltrating lobular carcinoma| 1.251 | 1.132–1.382  | <0.001 |
| Other                         | 1.175 | 1.054–1.309  | 0.004  |
| Tumor stage                   |      |              |        |
| T1                            | 1    |              |        |
| T2                            | 1.010 | 0.918–1.110  | 0.843  |
| T3                            | 1.129 | 1.016–1.254  | 0.024  |
| T4                            | 1.292 | 1.176–1.420  | <0.001 |
| Nodal stage                   |      |              |        |
| N0                            | 1    |              |        |
| N1                            | 0.955 | 0.886–1.030  | 0.236  |
| N2                            | 1.001 | 0.903–1.109  | 0.989  |
| N3                            | 1.055 | 0.960–1.158  | 0.267  |
| Risk stratification (SEER)    |      |              |        |
| Risk score 0                  | 1    |              |        |
| Risk score 1                  | 1.473 | 1.195–1.816  | <0.001 |
| Risk score 2                  | 2.437 | 1.979–3.001  | <0.001 |
| Risk score 3                  | 5.092 | 4.121–6.291  | <0.001 |
| Surgery                       |      |              |        |
| No                            | 1    |              |        |
| Yes                           | 0.608 | 0.570–0.648  | <0.001 |
| Unknown                       | 1.112 | 0.715–1.728  | 0.637  |
| Radiotherapy                  |      |              |        |
| No                            | 1    |              |        |
| Yes                           | 0.992 | 0.930–1.058  | 0.804  |
| Unknown                       | 0.796 | 0.648–0.979  | 0.031  |
| Chemotherapy                  |      |              |        |
| No                            | 1    |              |        |
| Yes                           | 0.876 | 0.817–0.938  | <0.001 |
| Bone metastasis               |      |              |        |
| No                            | 1    |              |        |
| Yes                           | 1.262 | 1.183–1.345  | <0.001 |
| Brain metastasis              |      |              |        |
| No                            | 1    |              |        |
| Yes                           | 2.128 | 1.910–2.371  | <0.001 |
| Liver metastasis              |      |              |        |
| No                            | 1    |              |        |
| Yes                           | 1.703 | 1.593–1.821  | <0.001 |
| Lung metastasis               |      |              |        |
| No                            | 1    |              |        |
| Yes                           | 1.216 | 1.141–1.296  | <0.001 |
| Other metastatic sites        |      |              |        |
| No                            | 1    |              |        |
| Yes                           | 1.029 | 0.914–1.158  | 0.639  |

CI confidence interval, HR hazard ratio, N nodal, T tumor, SEER surveillance, epidemiology, and end results.
of the novel or changing treatment approach for this population. Finally, the risk score staging system can frequently be used to define subgroups for inclusion in clinical trials.

The present analysis reveals the heterogeneity in the prognosis of the de novo stage IV breast cancer, and therefore, overcomes a significant limitation of the latest AJCC staging system, which does not include de novo stage IV disease. Although several studies have incorporated the biological factors into the substages of this population, only the histologic grade, ER, and HER2 were included in the scoring system for stratification, and the PR status was excluded. Another limitation of the previous studies was that the survival curves between risk score 0 and risk score 1 overlapped. In this study, a large cohort was used, and the BCSS curves could be clearly distinguished. Additionally, the risk score staging system developed in our study using the data from the SEER program (including grade, HER2, ER, and PR status) had a better predictive performance for BCSS than the MDACC risk score staging system (including grade, HER2, and ER status). Therefore, in order to better predict the prognosis and guide treatment decisions, these substages based on the risk score staging system should be introduced in the advanced setting similar to patients with non-metastatic disease. Additionally, the risk stratification based on the risk score staging system will undoubtedly serve as critical roles in patient care and research for this population.

Triple-negative breast cancer had the worst outcomes in de novo stage IV disease. In our study, we found that the median BCSS was less than 20 months in triple-negative breast cancer patients regardless of the histologic grades. However, it should be noted that in HER2-negative tumors, single HoR-positive tumors (ER+/PR− or ER−/PR+ subtypes) had lower BCSS than those of the double HoR-positive

Fig. 4 Comparison of breast cancer-specific survival by risk score for T1-4 patients using the SEER risk score staging system. a T1; b T2; c T3; d T4.
tumors, and had comparable BCSS to those of the double HoR-negative tumors. Our findings were similar to the findings of Bae et al., which indicated that a significant difference in prognosis between single HoR-positive tumors and double HoR-positive tumors, was only observed in HER2-negative tumors, and not in HER2-positive tumors. Several studies also confirmed that single HoR-positive tumors showed worse prognosis than double HoR-positive tumors in the HER2-negative group. No significant effect of single HoR-positive tumors in the prognostic assessment of HER2-positive tumors may be related to the results of trastuzumab treatment. In the 8th AJCC staging system, T2N0M0, G2/HER2−/ER+/PR+ patients are classified as stage IA, and G2/HER2−/ER+/PR−, G2/HER2−/ER−/PR−, G2/HER2−/ER−/PR+ patients are classified as stage IIB. Furthermore, consistent with our findings, the survival of HER2-negative and single HoR-positive tumors was comparable to that of double HoR-negative tumors according to the new AJCC pathological staging system. The aggressive behavior of single HoR-positive tumors indicated that the single HoR-positive tumors had distinct clinical and biological features. Therefore, in this study, we integrated single HoR-positive and double HoR-negative tumors into an aggressive subgroup. A recent study showed that the

Fig. 5  Comparison of breast cancer-specific survival by risk score for N0-3 patients using the SEER risk score staging system. a N0; b N1; c N2; d N3.
HER2−/ER+/PR− subtype exhibited more ZNF703 and RPS6KB1 amplification events than HER2−/ER+/PR+ tumors, which could promote cell proliferation, increase the stem cell population, chemotherapy resistance, tamoxifen resistance, and radiotherapy resistance. Therefore, further exploration of treatment strategies for single HoR-positive tumors are needed in the future to improve patient survival.

The 8th AJCC staging system incorporates the T stage, N stage, histologic grade, ER, PR, and HER2 status in the determination of the novel stages, but we did not include the T stage and N stage in this study due to the controversial effect of T and N stage on BCSS in patients with de novo stage IV breast cancer. Additionally, Li et al. reported that there was no difference in survival between node-negative and node-positive patients. Moreover, the current AJCC staging is mainly divided into clinical staging (all patients for clinical classification and staging) and pathological staging (for patients in whom surgery is the initial treatment), but the role of surgery in de novo stage IV disease remains controversial. Therefore, the significance of integrating T and N stages into the risk score staging system needs to be further explored in the future for this population.

An important caveat should be noted that the patients enrolled in the determination of AJCC 8th stages were treated with multimodal therapy according to the status of biologic factors. However, standard testing of biologic markers for evidence-based treatment might not be accessible to the majority of patients around the globe, especially those in low- and middle-income countries. Thus, the applicability of the risk score staging system to global patients may be compromised.

The role of local management in patients with de novo stage IV breast cancer remains controversial. In our study, we found that local surgery was associated with better BCSS for this population. However, conflict results were reported in the American Society of Clinical Oncology 2020 data. A retrospective study using the data from the National Cancer Database showed that primary tumor resection was associated with better overall survival in breast cancer patients with de novo stage IV disease. Another randomized trial from E2108 indicated that additional locoregional treatment to optimal systemic therapy did not improve progression-free survival or overall survival compared to those in optimal systemic therapy alone. According to our findings, it is worth carrying out further study to investigate the role of local management in de novo stage IV breast cancer after stratification by the risk score staging system.

Several limitations of the present analysis should be emphasized. First, the SEER database lacks sufficient details of the chemotherapy regimen, endocrine therapy, and anti-HER2 therapy. Second, comorbidity and performance status are also not recorded in the SEER database. Third, our study used BCSS in order to neutralize any confounding effects resulting from non-breast cancer-related death. In addition, the SEER program lacks a central pathology review for the biologic factors considered in the risk score staging system. Finally, the median follow-up period was short (29 months) in our study, which may have concealed some minor long-term effects among different stage categories.

In summary, the risk score staging system proposed in this study could be useful for more detailed stratification of de novo stage IV breast cancer and reflect the outcome of individualized treatment. Further studies involving larger sample sizes and more extended observation periods should be conducted to confirm the prognostic effect and validity of this staging system.

METHODS

Patients

Data for female breast cancer diagnosed between 2010 and 2014 were extracted from the population-based SEER database. Patients diagnosed with de novo stage IV breast cancer were included. Patients with de novo...
Stage IV breast cancer were defined as distant metastases known at the time of diagnosis or found during the initial staging workup prior to the first course of treatment. We excluded patients in which there was no pathological diagnosis, T0 stage, no data on T stage, N stage, tumor grade, HER2, ER, and PR status were also excluded. The patients with unknown metastatic sites, including bone, brain, liver, and lung, were also excluded. Moreover, patients without chemotherapy in HoR+/HER2+, HoR−/HER2+, and HoR−/HER2− subtypes were also excluded from this study. Our study was exempt from approval by the Institutional Review Board of the First Affiliated Hospital of Xiamen University because the SEER program provides de-identified information of patients.

Variables
The following variables of interest were extracted: age at diagnosis, race/ethnicity, histology, T stage, N stage, histological grade, ER status, PR status, HER2 status, radiotherapy, surgical procedures, and chemotherapy. In addition, the patterns of distant metastasis, including bone, brain, liver, lung, and other sites of metastasis, were included. TNM stage was determined based on the AJCC 7th staging system.

Statistical analysis
The primary outcome in the present study was BCSS, which was considered as the time from the initial diagnosis to death from breast cancer. The median BCSS and BCSS rate was estimated using the Kaplan–Meier method, and the effect of various subgroups on BCSS were compared by the log-rank test. ROC curve was used to evaluate the AUC, in order to compare the effect of different risk score staging systems in predicting BCSS. The independent prognostic factors associated with BCSS were determined with the multivariate Cox proportional hazard model. Sensitivity analyses focused on the T stage, N stage, the sites of distant metastasis, and the number of distant metastasis were performed. All data were analyzed by IBM SPSS version 22.0 (IBM Corp., Armonk, NY) and MedCalc 13.0 software (MedCalc Software BVBA, Ostend, Belgium). A P value < 0.05 was considered to indicate the statistical significance, and all tests were two-sided.

Reporting summary
Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper.
Table 5. Adjusted hazard ratios and the median BCSS in the risk score staging system in different subgroups.

| Stage | Risk score | Median BCSS (months) | HR  | 95% CI  | P     | Patterns of distant metastasis | Risk score | Median BCSS (months) | HR  | 95% CI  | P     |
|-------|------------|----------------------|-----|---------|-------|---------------------------------|------------|----------------------|-----|---------|-------|
| T1    | 0          | NA                   | <0.001 | 1 | Bone | 0 | 72 | <0.001 | 1 |
|       | 1          | 62                   | 1.847 | 1.059–3.223 | 0.031 | 1 | 48 | 1.606 | 1.238–2.084 | <0.001 |
|       | 2          | 39                   | 3.177 | 1.814–5.566 | <0.001 | 2 | 32 | 2.636 | 2.032–3.419 | <0.001 |
|       | 3          | 19                   | 5.664 | 3.163–10.145 | <0.001 | 3 | 15 | 5.048 | 3.859–6.602 | <0.001 |
| T2    | 0          | NA                   | <0.001 | 1 | Brain | 0 | 44 | <0.001 | 1 |
|       | 1          | 59                   | 1.601 | 1.101–2.327 | 0.014 | 1 | 20 | 1.866 | 0.979–3.559 | 0.058 |
|       | 2          | 42                   | 2.571 | 1.767–3.740 | <0.001 | 2 | 14 | 2.970 | 1.558–5.661 | 0.001 |
|       | 3          | 21                   | 5.666 | 3.859–8.321 | <0.001 | 3 | 8 | 4.996 | 2.588–9.645 | <0.001 |
| T3    | 0          | NA                   | <0.001 | 1 | Liver | 0 | 44 | <0.001 | 1 |
|       | 1          | 53                   | 1.065 | 0.648–1.749 | 0.804 | 1 | 38 | 1.256 | 0.898–1.756 | 0.183 |
|       | 2          | 39                   | 1.685 | 1.029–2.757 | 0.038 | 2 | 27 | 1.987 | 1.426–2.769 | <0.001 |
|       | 3          | 16                   | 3.856 | 2.341–6.352 | <0.001 | 3 | 13 | 4.275 | 3.040–6.010 | <0.001 |
| T4    | 0          | NA                   | <0.001 | 1 | Lung | 0 | 72 | <0.001 | 1 |
|       | 1          | 44                   | 1.383 | 0.982–1.948 | 0.063 | 1 | 41 | 1.893 | 1.301–2.755 | 0.001 |
|       | 2          | 28                   | 2.374 | 1.692–3.329 | <0.001 | 2 | 27 | 3.144 | 2.162–4.573 | <0.001 |
|       | 3          | 14                   | 4.780 | 3.394–6.733 | <0.001 | 3 | 15 | 5.933 | 4.059–8.670 | <0.001 |
| N0    | 0          | 70                   | <0.001 | 1 | Other sites | 0 | 77 | <0.001 | 1 |
|       | 1          | 49                   | 1.853 | 1.228–2.796 | 0.003 | 1 | NA | 0.866 | 0.474–1.582 | 0.640 |
|       | 2          | 33                   | 2.818 | 1.861–4.267 | <0.001 | 2 | 51 | 1.644 | 0.915–2.954 | 0.096 |
|       | 3          | 19                   | 4.694 | 3.059–7.216 | <0.001 | 3 | 24 | 3.804 | 2.119–6.830 | <0.001 |
| N1    | 0          | 72                   | <0.001 | 1 | One sitea | 0 | NA | <0.001 | 1 |
|       | 1          | 51                   | 1.258 | 0.936–1.692 | 0.128 | 1 | 59 | 1.501 | 1.104–2.040 | 0.010 |
|       | 2          | 34                   | 2.165 | 1.613–2.904 | <0.001 | 2 | 41 | 2.414 | 1.778–3.277 | <0.001 |
|       | 3          | 16                   | 4.694 | 3.479–6.334 | <0.001 | 3 | 19 | 5.182 | 3.800–7.066 | <0.001 |
| N2    | 0          | NA                   | <0.001 | 1 | Two sitesa | 0 | 72 | <0.001 | 1 |
|       | 1          | 58                   | 1.439 | 0.758–2.731 | 0.266 | 1 | 38 | 1.901 | 1.270–2.846 | 0.002 |
|       | 2          | 39                   | 2.348 | 1.224–4.432 | 0.008 | 2 | 25 | 3.007 | 2.008–4.502 | <0.001 |
|       | 3          | 15                   | 5.602 | 2.935–10.692 | <0.001 | 3 | 11 | 5.601 | 3.714–8.448 | <0.001 |
| N3    | 0          | NA                   | <0.001 | 1 | Three-four sitesa | 0 | 36 | <0.001 | 1 |
|       | 1          | 57                   | 1.683 | 0.955–2.964 | 0.072 | 1 | 25 | 1.217 | 0.698–2.121 | 0.488 |
|       | 2          | 37                   | 2.892 | 1.649–5.073 | <0.001 | 2 | 14 | 2.139 | 1.235–3.707 | 0.007 |
|       | 3          | 17                   | 6.581 | 3.736–11.596 | <0.001 | 3 | 8 | 3.632 | 2.041–6.463 | <0.001 |

BCSS breast cancer-specific survival, CI confidence interval, HR hazard ratio, N nodal, NA none available, T tumor.
*aIndicates four metastatic sites, including bone, brain, liver, and lung.

DATA AVAILABILITY

The datasets supporting the findings of this study were extracted from the population-based SEER database (https://seer.cancer.gov/). The data will be made available to researchers who have obtained permission from the SEER programme. Please contact the corresponding author, Dr Yuan Zhou, email address: zhouJuan@xmu.edu.cn, or the SEER program, https://seer.cancer.gov/seertrack/data/request/, for data access requests. A metadata record describing the datasets generated and analysed during the current study, is available in figshare: https://doi.org/10.6084/m9.figshare.12668543.

CODE AVAILABILITY

The codes used during the current study are available from the corresponding author on reasonable request without undue qualification.

Received: 25 February 2020; Accepted: 6 August 2020; Published online: 07 September 2020

REFERENCES

1. Iqbal, J. et al. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA 313, 165–173 (2015).
2. Hölzel, D. et al. Survival of de novo stage IV breast cancer patients over three decades. J. Cancer Res. Clin. Oncol. 143, 509–519 (2017).
3. Co, M. et al. De-novo metastatic breast cancers with or without primary tumor resection—a 10-year study. Cancer Treat. Res. Commun. 19, 100118 (2019).
4. Soran, A. et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01. Ann. Surg. Oncol. 25, 3141–3149 (2018).
5. Wu, S. G. et al. The effect of distant metastases sites on survival in de novo stage-IV breast cancer: a SEER database analysis. Tumour Biol. 39, 1010428317705082 (2017).
6. Neuman, H. B. et al. Stage IV breast cancer in the era of targeted therapy: does surgery of the primary tumor matter? Cancer 116, 1226–1233 (2010).
7. Rossi, V. et al. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. Breast 23, 44–49 (2014).
8. Lambertini, M. et al. Patterns of care and clinical outcomes of HER2-positive metastatic breast cancer patients with newly diagnosed stage IV or recurrent disease undergoing first-line trastuzumab-based therapy: a multicenter retrospective cohort study. *Clin. Breast Cancer* 17, 601–610 (2017).

9. Yardley, D. A. et al. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. *Breast Cancer Res. Treat.* 145, 725–734 (2014).

10. Li, X. et al. Loco-regional surgical treatment improves the prognosis in primary metastatic breast cancer patients with a single distant metastasis except for brain metastasis. *Breast* 45, 104–112 (2019).

11. Lu, X. et al. Predicting features of breast cancer with gene expression patterns. *Breast Cancer Res. Treat.* 108, 191–201 (2008).

12. Rakha, E. A. et al. Breast cancer prognostic classification in the molecular era: the role of the histological grade. *Breast Cancer Res. Staging*. 12, 207 (2010).

13. Amin, M. B. et al. *AJCC Cancer Staging Manual*. 8th edn (Springer International Publishing, New York, 2018).

14. Lee, S. B. et al. A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer. *Breast Cancer Res. Treat.* 169, 257–266 (2018).

15. Plichta, J. K. et al. Implications for breast cancer restaging based on the 8th edition AJCC staging manual. *Ann. Surg.* 271, 169–176 (2020).

16. Kim, I. et al. Prognostic validation of the American Joint Committee on Cancer 8th Staging System in 24,014 Korean patients with breast cancer. *J. Breast Cancer* 21, 173–181 (2018).

17. Weiss, A. et al. Validation study of the American Joint Committee on Cancer Breast Cancer: Eighth Edition Prognostic Stage compared with the anatomic stage in breast cancer. *JAMA Oncol.* 4, 203–209 (2018).

18. Chavez-MacGregor, M. et al. Incorporating tumor characteristics to the American Joint Committee on cancer breast cancer staging system. *Oncologist* 22, 1292–1300 (2017).

19. Kantor, O. et al. Comparative analysis of proposed strategies for incorporating biologic factors into breast cancer staging. *Ann. Surg. Oncol.* 27, 2229–2237 (2020).

20. Bae, S. Y. et al. Poor prognosis of single hormone receptor-positive breast cancer: similar outcome as triple-negative breast cancer. *Bmc. Canc. Res. 15*, 138 (2015).

21. Park, C. et al. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer. *World J. Surg. Oncol.* 14, 244 (2016).

22. Sun, J. Y. et al. Progesterone receptor loss identifies hormone receptor-positive and HER2-negative breast cancer subgroups at higher risk of relapse: a retrospective cohort study. *Onco Targets Ther.* 9, 1707–1713 (2016).

23. Zong, Y. et al. Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study. *PLoS ONE* 9, e95629 (2014).

24. Cancellari, G. et al. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. *Ann. Oncol.* 24, 661–668 (2013).

25. Liu, X. Y. et al. Genomic landscape and endocrine-resistant subgroup in estrogen receptor-positive, progesterone receptor-negative, and HER2-negative breast cancer. *Theranostics* 8, 6386–6399 (2018).

26. Holland, D. G. et al. ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. *EMBO Mol. Med.* 3, 167–180 (2011).

27. Sircoulomb, F. et al. ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. *EMBO Mol. Med.* 3, 153–166 (2011).

28. Pérez-Tenorio, G. et al. Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer. *Breast Cancer Res. Treat.* 138, 713–723 (2011).

29. Bärlund, M. et al. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. *J. Natl Cancer Inst.* 92, 1252–1259 (2000).

30. van der Hage, J. A. et al. Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients. Br. J. Cancer *90*, 1543–1550 (2004).

31. Badwe, R. et al. Loco-regional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. *Lancet Oncol.* 16, 1380–1388 (2015).

32. Rapits, E. et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. *J. Clin. Oncol.* 24, 2743–2749 (2006).

33. Lane, W. O. et al. Surgical resection of the primary tumor in women with de novo stage IV breast cancer: contemporary practice patterns and survival analysis. *Ann. Surg.* 269, 537–544 (2019).

34. de Souza, J. A. et al. Global health equity: cancer care outcome disparities in high-, middle-, and low-income countries. *J. Clin. Oncol.* 34, 6–13 (2016).

35. Bilani, N. et al. Surgery at primary and metastatic sites for stage IV breast cancer (BC): a National Cancer Database (NCDB) analysis. *J. Clin. Oncol.* 38(15_suppl), 1099–1099 (2020).

36. Khan, S. A. et al. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: a trial of the ECOG-ACRIN Research Group (E2108). *J. Clin. Oncol.* 38(18_suppl), LB2A–LB2A (2020).

37. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence—SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2018 Sub (1973–2016 varying)—Linked To County Attributes—Total U.S., 1969–2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, based on the November 2018 submission. www.seer.cancer.gov (2018).

38. He, Z. Y. et al. Metadata supporting the published article: Incorporation of biologic factors for the staging of de novo stage IV breast cancer. figshare. https://doi.org/10.6084/m9.figshare.12668543 (2020).

ACKNOWLEDGEMENTS

This work was partly supported by the National Natural Science Foundation of China (No. 81802600, 81872459), the Commission Young and Middle-aged Talents Training Project of Fujian Health Commission (No. 2019-ZQN825), and the National Science Foundation of Guangdong Province (No. 2018A030313666, 2017A030310422).

AUTHOR CONTRIBUTIONS

Z.Y.H., C.L.L., J.W., J.Z., and S.G.W. are lead authors who participated in data collection, manuscript drafting, table/figure creation, and manuscript revision. J.W., J.L., and L.H. are senior authors who aided in drafting the manuscript and manuscript revision. J.Z. and S.G.W. are the corresponding authors who initially developed the concept and drafted and revised the manuscript. All authors read and approved the final manuscript.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information is available for this paper at https://doi.org/10.1038/s41523-020-00186-5.

Correspondence and requests for materials should be addressed to J.Z. or S.G.W.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.